Norovirus causes an average of 900 deaths annually mostly among older adults, 109,000 hospitalizations, and 19 million to 21 million cases in the U.S. each year.

We aren't quite clear of peak norovirus season just yet, and if you come down with the debilitating virus, the symptoms could linger in your system for some time. Here's what you need to know if ...

The University of Virginia on Wednesday said seven people at the school have confirmed cases of norovirus. The virus is highly contagious and causes vomiting and diarrhea, according to the Centers ...

Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its second-generation oral norovirus vaccine pill, with antibody responses up 141% ...

Vaxart's (NASDAQ:VXRT) shares rose following the positive results from an early-stage trial of its new oral pill vaccine for norovirus, a more advanced version compared to its first-generation ...

The Centers for Disease Control and Prevention reported 91 norovirus outbreaks during the week of Dec. 5, 2024; a 32% increase compared to the previous week, DPHSS said.

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

But it’s worth it. I wanted to share with you, as a neighbor, that our whole community is really involved in this quest to conquer norovirus.

Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025.

Vaxart CEO Steven Lo stated that the company believes its second-generation norovirus oral pill vaccine candidate "has the potential to provide first-in-class or best-in-class protection" against ...

Company News Published 06/11/2025, 07:37 AM 0 Vaxart reports improved antibody response in norovirus vaccine trial VXRT -2.51% ...